HALO Quote, Financials, Valuation and Earnings

Pulmonx has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -69.38%. Halozyme Therapeutics's return on equity of 156.62% beat Pulmonx's return on equity of -51.95%.

Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 35.97%. On the other hand Pulmonx has an analysts' consensus of -- which suggests that it could grow by 90.36%. Given that Pulmonx has higher upside potential than Halozyme Therapeutics, analysts believe Pulmonx is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Pulmonx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulmonx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Pulmonx pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Pulmonx quarterly revenues of $20.4M. Halozyme Therapeutics's net income of $137M is higher than Pulmonx's net income of -$14.1M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.62x while Pulmonx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.46x versus 3.06x for Pulmonx. Usually stocks with elevated PS ratios are considered overvalued.

Lexicon Pharmaceuticals has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -3703.49%. Halozyme Therapeutics's return on equity of 156.62% beat Lexicon Pharmaceuticals's return on equity of -115.11%.

Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 35.97%. On the other hand Lexicon Pharmaceuticals has an analysts' consensus of $3.60 which suggests that it could grow by 335.31%. Given that Lexicon Pharmaceuticals has higher upside potential than Halozyme Therapeutics, analysts believe Lexicon Pharmaceuticals is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Lexicon Pharmaceuticals has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.862%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexicon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Lexicon Pharmaceuticals pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Lexicon Pharmaceuticals quarterly revenues of $1.8M. Halozyme Therapeutics's net income of $137M is higher than Lexicon Pharmaceuticals's net income of -$64.8M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.62x while Lexicon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.46x versus 45.98x for Lexicon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of -143.53%. Halozyme Therapeutics's return on equity of 156.62% beat Novavax's return on equity of --.

Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 35.97%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 85.19%. Given that Novavax has higher upside potential than Halozyme Therapeutics, analysts believe Novavax is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison Novavax has a beta of 2.017, suggesting its more volatile than the S&P 500 by 101.749%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than Novavax quarterly revenues of $84.5M. Halozyme Therapeutics's net income of $137M is higher than Novavax's net income of -$121.3M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.62x while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.46x versus 1.50x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of 47.23% compared to Halozyme Therapeutics's net margin of 3.88%. Halozyme Therapeutics's return on equity of 156.62% beat TransMedics Group's return on equity of 19.83%.

Halozyme Therapeutics has a consensus price target of $64.13, signalling upside risk potential of 35.97%. On the other hand TransMedics Group has an analysts' consensus of $102.00 which suggests that it could grow by 62.81%. Given that TransMedics Group has higher upside potential than Halozyme Therapeutics, analysts believe TransMedics Group is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.226, which suggesting that the stock is 22.555% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.81%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $290.1M, which are larger than TransMedics Group quarterly revenues of $108.8M. Halozyme Therapeutics's net income of $137M is higher than TransMedics Group's net income of $4.2M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 15.62x while TransMedics Group's PE ratio is 66.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.46x versus 5.40x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.